C-KIT EXPRESSION AND CORRELATION WITH CHEMOTERAPY RESISTANCE IN OVARIAN CARCINOMA: AN IMMUNOCYTOCHEMICAL STUDY by Raspollini, M. et al.
Annals of Oncology 15: 594–597, 2004Original article DOI: 10.1093/annonc/mdh139
© 2004 European Society for Medical Oncology
c-KIT expression and correlation with chemotherapy resistance in 
ovarian carcinoma: an immunocytochemical study 
M. R. Raspollini1*, G. Amunni2, A. Villanucci2, G. Baroni1, A. Taddei3 & G. L. Taddei1
*Correspondence to: Dr M. R. Raspollini, Department of Human Pathology 
and Oncology, University of Florence, Viale GB Morgagni, 85-50134 
Florence, Italy. Tel: +39-055-4478138; Fax: +39-055-4379868; 
E-mail: mariarosaria.raspollini@unifi.it
1Department of Human Pathology and Oncology, 2Department of Gynecology, Perinatology and Reproductive Medicine, 3Department of Surgery, 
University of Florence, Florence, Italy
Received 2 September 2003; revised 17 December 2003; accepted 22 December 2003
Background: Recent studies have shown that several tumours express c-KIT, a growth factor receptor with
tyrosine kinase activity; moreover, clinical results have shown the efficacy of the tyrosine kinase inhibitor,
STI571, in c-KIT-positive tumours. The aim of this study was to determine the incidence and correlation with
chemotherapy resistance of c-KIT expression in advanced serous, low grade of differentiation, ovarian carcinoma.
Patients and methods: We performed an immunohistochemistry analysis of 56 patients with advanced
serous ovarian carcinomas using archival paraffin-embedded specimens.
Results: Intense c-KIT immunostaining was observed in 51.7% of cases. c-KIT expression was statistically
correlated with progression of disease after first-line chemotherapy (P = 0.029).
Conclusions: c-KIT is also expressed in ovarian carcinoma and it is statistically correlated with chemotherapy
resistance. This study suggests the necessity for clinical trials confirming the utility of the tyrosine kinase inhibitor,
STI571, in ovarian advanced cancer patients with c-KIT overexpression when these patients have shown no
clinical response to conventional chemotherapy.
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Introduction
Ovarian cancer is the most common gynaecological malignancy
causing death in Europe and North America. Its insidious growth
pattern is associated with few specific early symptoms and as a
result generally leads to diagnosis of advanced stage disease on
clinical examination. Approximately 90% of all patients with
ovarian carcinoma underwent surgery followed by chemotherapy.
Ovarian cancer is a chemosensitive tumour; numerous chemothera-
peutic drugs can produce an objective remission in the majority of
cases. Moreover, patients with platinum-resistant ovarian cancer
that does not respond to initial therapy, or who have disease that
recurs after a short treatment-free interval following first-line
therapy, pose a particular problem. In these patients alternate
therapeutic options are clearly warranted.
STI571 is a small molecule that selectively inhibits the enzym-
atic activity of several tyrosine kinases, such as the growth factor
receptor with tyrosine kinase activity, a product of the c-kit gene
[1–2]. The physiological ligand is the cytokine stem cell factor
(SFC), also called mast cell growth factor or Steel factor [3].
Mutations of c-KIT that cause constitutive activation of the tyrosine
kinase function of c-KIT are detectable in most gastrointestinal
stromal tumours (GISTs) [4]. Following initial observations of
c-KIT expression and its correlation with bad prognosis in GISTs
[5] and because c-KIT seems to be also expressed in ovarian
carcinoma [6–9], we have evaluated the presence of c-KIT over-
expression in advanced ovarian carcinoma for a new therapeutic
prospective: a highly targeted and tailored cancer therapy.
The aim of this study was the examination of the presence of
c-KIT and its correlation with chemotherapy resistance compar-
atively on the response to first-line chemotherapy of a series of
advanced serous ovarian, low grade of differentiation, carcinoma
patients who had undergone the same surgical and chemothera-
peutic treatment.
Patients and methods
Case selection
We have studied 56 consecutive cases of International Federation of Gynecology
and Obstetrics (FIGO) stage III ovarian serous carcinoma, grade 3, collected
from the files of the Department of Human Pathology and Oncology, University
of Florence, from 1985 to 1999. The specimens came from 56 patients with
known follow-up, who had undergone surgical and chemotherapy treatment at
the Department of Gynecology, Perinatology and Reproductive Medicine,
University of Florence. Fully informed consent was obtained from all patients
prior to surgery, and tumour samples were collected during surgery. All the
patients underwent laparotomy for optimal debulking of the gross neoplastic
masses with abdominal hysterectomy, bilateral salpingo-oophorectomy,
appendectomy and omentectomy with careful examination of all serosal surfaces
and biopsies of any suspected lesions. All the patients presented minimal/
absent or bulk (>2 cm) residual disease after surgery.
A postoperative treatment was performed in all patients, and it consisted of
combined chemotherapy regimens with modified PEC (six cycles of cisplatin
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80 mg/m2 and cyclophosphamide 800 mg/m2 alternating with six cycles of
cisplatin 80 mg/m2 and epidoxorubicin 75 mg/m2) prior to 1997, and after this
with combination chemotherapy with six cycles of carboplatin AUC 5 and
paclitaxel 175 mg/m2/3 h.
We have evaluated the clinical response to first-line chemotherapeutic treat-
ment according to World Health Organization (WHO) methods [10]: complete
response (CR), partial response (PR), stable disease (SD) and progressive
disease (PD). The new Response Evaluation Criteria in Solid Tumours
(RECIST) guidelines were evaluated with ultrasonography and CT.
We considered c-KIT expression (positive versus negative), measured
using immunohistochemical analysis, in ovarian carcinoma in relation to
response to first-line chemotherapy.
A treatment-free interval (TFI) of <6 months was established when the
disease recurred <6 months after the completion of primary therapy [11–13].
TFI was defined as the interval time from primary treatment to recurrence and/
or metastasis. Cause-specific survival was defined as the survival time from
primary treatment to death due to the disease.
Tissue specimens and immunohistochemistry
Specimens were obtained by surgical resection in all cases and fixed in 10%
formalin before being processed in paraffin. Hematoxylin–eosin stained
sections from each histological specimen were reviewed by two pathologists
to confirm the histological diagnosis. One representative paraffin block was
selected from each case for further study. For immunohistochemical analysis,
3 µm sections were prepared, each section was deparaffinised using xylene
and subsequent hydration. The immunohistochemical studies were performed
using the streptavidin–biotin–peroxidase method (UltraVision kit; LAB
Vision, Fremont, CA) with diaminobenzidine (DAB) as chromogen and
Mayer’s hematoxylin as nuclear counterstain. The assays were performed
entirely on an automated stainer (BenchMark model; Ventana, Tucson, AZ).
Negative and positive controls were included with each run. Sections of
strongly positive c-KIT GIST were used as positive control. Negative controls
were performed by substituting the primary antibody with non-immune mouse
serum. Mast cells in the c-KIT-negative cases acted as a positive internal con-
trol. The immunohistochemically stained sections were evaluated without
knowledge of the clinical outcome of each patient.
Evaluation of immunohistochemical staining
Positive stain appeared as a cytoplasmic and/or membranous stain. The per-
centage of positive cells and the degree and cellular distribution of the staining
were scored. Only cases showing ≥20% moderate to strong membranous
and/or cytoplasmic positivity were scored as positive. No background or non-
specific staining of tumour stroma or adjacent ovarian parenchyma was
encountered other than positivity in mast cells as expected [14].
To assess interobserver variability in the evaluation of c-KIT expression,
the evaluations of one author (M.R.R.) were compared with those of one of the
other authors (G.L.T.). Initially the slides were evaluated independently, and
those graded diversely were subsequently re-evaluated by the two authors
together under a discussion microscope.
Statistical analysis
Fisher’s exact test was used to analyse the distribution of c-KIT-positive cases
according to clinical response to chemotherapy. A value of P ≤0.05 was
considered to be statistically significant.
Results
The follow-up period for each patient was until death or ≥5 years
after surgery; the median and mean follow-up were 28 and
38.5 months, respectively, with observed values ranging from
11 to 105 months from the time of surgery and first-line adjuvant
therapy. Thirty-one patients presented minimal/absent residual
disease after surgery and 25 patients presented bulk (>2 cm) residual
disease after surgery.
A complete response to first-line chemotherapy was achieved in
34 patients and a partial response in five patients. None of the
patients had stable disease; 17 patients progressed during chemo-
therapy.
Intense c-KIT immunostaining was observed in the cytoplasm
of tumour cells in 29 cases (51.7%). Figure 1 shows a representative
example of a serous ovarian carcinoma with intense c-KIT expres-
sion. Figure 2 shows mast cells in a c-KIT-negative ovarian
carcinoma which act as an internal c-KIT-positive control.
Correlation of c-KIT expression with clinicopathological 
parameters
c-KIT expression is statistically correlated with progression of
disease after first-line chemotherapy (P = 0.029; Table 1).
Figure 1. A representative example of a serous ovarian carcinoma with 
intense c-KIT expression. 
Figure 2. c-KIT-positive internal control: mast cells in a c-KIT-negative 
ovarian carcinoma.
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We observed bulk residual disease following surgery in 15
(51.7%) c-KIT-positive patients and in 10 (37%) c-KIT-negative
patients. We also observed a shorter mean TFI and a shorter mean
overall survival in c-KIT-positive patients with respect to c-KIT-
negative patients. In fact, the mean TFI was 12.7 months in c-KIT-
positive cases and 18.4 months in c-KIT-negative cases. The
mean overall survival was 31.7 months in c-KIT-positive cases,
and 36.8 months in c-KIT-negative cases. c-KIT status was not
correlated with residual disease following surgery (minimal/
absent versus bulk) nor with clinical outcome.
Discussion
In the current study, c-KIT overexpression detected using immuno-
histochemistry is observed in approximately half of the ovarian
cancers. Thus, the results of this study support the presence of
c-KIT in ovarian cultured cells [8], and the hypothesis that c-KIT
may also play a critical role in the pathogenesis of ovarian carcinoma
[6].
Our results showed that c-KIT-positive cases were less responsive
to chemotherapy than c-KIT-negative cases; in fact, c-KIT
expression is correlated with progression of disease after first-line
chemotherapy. Perhaps c-KIT status may help clinicians identify
those patients who would benefit from a different therapeutic
approach. Mutation-positive GISTs showed more frequent recur-
rences and resulted in higher mortality than the mutation-negative
GISTs during comparable follow-up periods [5]. Moreover, a
more aggressive biological behaviour of c-KIT-positive cases has
also been observed in other malignancies, such as small-cell lung
cancer [15] and sarcomas [16].
c-KIT is not only a biochemical marker; its involvement in an
autocrine, paracrine or endocrine growth loop may represent a
molecular mechanism behind aggressive tumour growth [17–18].
The tyrosine kinase inhibitor STI571 has recently attracted
much interest [19]. Clinical results obtained with innovative
targeted cancer therapies suggest that the major molecular
mechanisms that drive tumour growth need to be identified before
rational selection of appropriately targeted cancer therapies is
possible, based on the specific molecular abnormality in neoplastic
cells, such as in chronic myeloid leukaemia [20, 21] and in GISTs
[22–23]. c-KIT overexpression in patients with extensive-stage
small-cell lung carcinoma [15, 24] and ocular melanoma and
liposarcoma [25] may be a potential target for specific immuno-
therapy with STI571.
Thus, the results of the present study and all these observations
provide a rationale for therapeutic intervention aimed at c-KIT
expression, particularly in c-KIT-positive ovarian cancer patients
with extensive disease; a patient population to whom clinicians
currently have little to offer, and for whom new therapeutic strate-
gies are urgently needed.
Therapeutic concepts could include the inhibition of c-KIT with
humanized monoclonal antibodies. This approach has already been
successfully applied in breast cancer patients using a humanized
monoclonal antibody that blocks the extracellular domain of the
HER/neu receptor [26].
The current study supports further clinical trials to confirm the
utility of the tyrosine kinase inhibitor, STI571, in ovarian
advanced cancer patients with c-KIT overexpression, if these
patients have shown no clinical response to conventional chemo-
therapy.
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